SECTOR OF CARE VARIATIONS IN PRESCRIPTIONS OF SGLT2 INHIBITORS (SGLT2I) AND GLP-1 RECEPTOR AGONISTS (GLP-1 RA) IN THE US MILITARY HEALTH SYSTEM (MHS)

被引：0
|
作者：
Nguyen, Julia [1 ]
Nee, Robert [1 ,2 ]
Marneweck, Hava [3 ]
Banaag, Amanda [3 ]
Koehlmoos, Tracey [2 ]
Oliver, James [1 ,2 ]
机构：
[1] Walter Reed Natl Mil Med Ctr, Bethesda, MD 20814 USA
[2] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA
[3] Henry M Jackson Fdn Advacement Mil Med Inc, Bethesda, MD 20817 USA
来源：
AMERICAN JOURNAL OF KIDNEY DISEASES | 2025年 / 85卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
G-371
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Positioning of GLP-1 receptor agonists and SGLT2 inhibitors: what do the guidelines say in diabetes?
    Darmon, P.
    CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION, 2023, 27 (02): : 62 - 65
  • [22] A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment
    Consoli, Agostino
    Formoso, Gloria
    Baldassarre, Maria Pompea Antonia
    Febo, Fabrizio
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (03) : 293 - 302
  • [23] GLP-1 Receptor Agonists Among Patients With Overweight or Obesity, Diabetes, and HFpEF on SGLT2 Inhibitors
    Patel, Rushin
    Wadid, Mark
    Makwana, Bhargav
    Kumar, Ashish
    Khadke, Sumanth
    Bhatti, Ammar
    Banker, Ahan
    Husami, Zaid
    Labib, Sherif
    Venesy, David
    Fonarow, Gregg
    Kosiborod, Mikhail
    Al-Kindi, Sadeer
    Bhatt, Deepak L.
    Dani, Sourbha
    Nohria, Anju
    Butler, Javed
    Ganatra, Sarju
    JACC-HEART FAILURE, 2024, 12 (11) : 1814 - 1826
  • [24] SGLT2 inhibitors and GLP-1 receptor agonists: which is the best anti-frailty drug?
    Mone, Pasquale
    Ciccarelli, Michele
    Jankauskas, Stanislovas S.
    Guerra, Germano
    Vecchione, Carmine
    Visco, Valeria
    Santulli, Gaetano
    LANCET HEALTHY LONGEVITY, 2024, 5 (09):
  • [25] Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes
    Nagahisa, Taichi
    Saisho, Yoshifumi
    DIABETES THERAPY, 2019, 10 (05) : 1733 - 1752
  • [26] SGLT2 Inhibitors or GLP-1 Receptor Agonists Reduce Cardiovascular Outcomes in Patients with Type 2 Diabetes
    Shaughnessy, Allen F.
    AMERICAN FAMILY PHYSICIAN, 2021, 104 (02) : 206 - 206
  • [27] Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease
    Li, Jiahua
    Albajrami, Oltjon
    Zhuo, Min
    Hawley, Chelsea E.
    Paik, Julie M.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2020, 15 (11): : 1678 - 1688
  • [28] Choosing GLP-1 receptor agonists or SGLT-2 inhibitors by cardiorenal risk
    Bailey, Clifford J.
    LANCET DIABETES & ENDOCRINOLOGY, 2020, 8 (02): : 97 - 99
  • [29] Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes
    Taichi Nagahisa
    Yoshifumi Saisho
    Diabetes Therapy, 2019, 10 : 1733 - 1752
  • [30] Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes
    Edmonston, Daniel
    Mulder, Hillary
    Lydon, Elizabeth
    Chiswell, Karen
    Lampron, Zachary
    Shay, Christina
    Marsolo, Keith
    Shah, Raj C.
    Jones, W. Schuyler
    Gordon, Howard
    Hwang, Wenke
    Ayoub, Isabella
    Ford, Daniel
    Chamberlain, Alanna
    Rao, Ajaykumar
    Fonseca, Vivian
    Chang, Alexander
    Ahmad, Faraz
    Hung, Adriana
    Hunt, Kelly
    Butler, Javed
    Bosworth, Hayden B.
    Pagidipati, Neha
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 84 (08) : 696 - 708
12345